Phase i dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2318-2326

  Massard, C ^a   Salazar, R ^b   Armand, J P ^a   Majem, M ^b   Deutsch, E ^a   Garcia M ^b   Oaknin, A ^b   Fernndez Garcia E M ^c   Soto, A ^c   Soria, J C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c PHARMAMAR S A   (Spain)

Author keywords

Dose escalation; ES 285; Pharmacokinetics; Phase I study; Spisulosine

Indexed keywords

ANTINEOPLASTIC AGENT; ES 285; SPISULOSINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; APHASIA; APRAXIA; ARTICLE; ASTHENIA; ATAXIA; CANCER SURVIVAL; CLINICAL ARTICLE; CONFUSION; COUGHING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; INJECTION SITE EXTRAVASATION; LYMPHOCYTOPENIA; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 84875512486     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9772-8     Document Type: Article

References (16)

1. Faircloth G, Cuevas C, Kahalalide F, ES285 (2006) Potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363-379
2. Den Brok MW, Nuijen B, Meijer DM et al (2005) Pharmaceutical development of a parenteral lyophilised formulation of the inves-tigational anticancer agent ES-285.HCl. PDA J Pharm Sci Technol 59:246-257
3. Den Brok MW, Nuijen B, Garcia JL et al (2006) Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl- beta-cyclodextrin in infusion devices. Pharmazie 61:21-24
4. Cuadros R, Montejo E, Wendosell F, et al. (2000) The effects of spisulosine (ES-285), a marine natural product, on the morphology and survival of tumor cells. 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, November 7-10
5. Cuadros R, Montejo de Garcini E, Wandosell F et al (2000) The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett 152:23-29
6. Baird R, Clarke P, Workman P (2005) ES-285, a novel marine anticancer agent: investigation of mechanism of action using gene expression microarrays. AACR Meeting Abstracts: 970
7. Alvarez-Miranda M, Rodriguez-Gonzalez A, Ramirez de Molina A, et al. (2007) ES-285 an anticancer agent of marine origin that acts through the ceramide pathway. AACR Meeting Abstracts: 1444
8. Sanchez AM, Malagarie-Cazenave S, Olea N et al (2008) Spisu-losine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur J Pharmacol 584:237-245
9. Salcedo M, Cuevas C, Alonso JL et al (2007) The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. Apoptosis 12:395-409
10. Baird DB, Kitzen J, Clarke PA et al (2009) Phase I safety, phar-macokinetic and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol Cancer Ther 8(6):1430-1437
11. Vilar E, Grünwald V, Schöffski P, et al. (2010) A phase I dose-escalating study of ES-285, a marine sphingolypidderived compound, with repeat-dose administration in patients with advanced solid tumors. Invest New Drugs vol. in press: 1-7
12. Schöffski P, Dumez H, Ruijter R, et al. (2011) Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advance solid malignancies. Cancer Chemother Pharmacol vol. in press: 1-7
13. Massard C, Majem M, Soria JC, et al. (2007) A phase I (3 h infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors. AACR Meeting Abstracts (Molecular Targets Meeting)
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
15. Stokvis E, Nan-Offeringa L, Rosing H et al (2003) Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chroma-tography and tandem mass spectrometry. J Mass Spectrom 38 (5):548-554
16. Stokvis E, Rosing H, López-Lazaro L et al (2004) A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. Biomed Chromatogr 18:403-407